Catalyst Pharmaceuticals Announces 11th Circuit Court of Appeals Denial of Jacobus Pharmaceutical Company Inc.'s Petition for Rehearing
10 janv. 2022 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals Announces DyDo Pharma Initiation of a Phase 3 Study for FIRDAPSE® (amifampridine) in Japan
06 déc. 2021 07h00 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference
15 nov. 2021 16h15 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals Reports Third Quarter 2021 Financial Results
09 nov. 2021 16h14 HE
|
Catalyst Pharmaceuticals, Inc.
Continued Strong Financial and Operational Performance in the Third Quarter 2021FIRDAPSE® Revenue of $35.9 Million Increased 23.1% Compared to Third Quarter 2020Plans to Seek to Expand the U.S....
Catalyst Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 9, 2021
25 oct. 2021 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...